Header Logo

Connection

NAVEEN PEMMARAJU to Skin Neoplasms

Back to Details
This is a "connection" page, showing publications NAVEEN PEMMARAJU has written about Skin Neoplasms.
NAVEEN PEMMARAJU
Connection Strength
3.976
Skin Neoplasms
  1. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e130-e137.
    View in: PubMed
    Score: 0.294
  2. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia. 2023 09; 37(9):1767-1778.
    View in: PubMed
    Score: 0.285
  3. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol. 2023 May; 21(5):257-264.
    View in: PubMed
    Score: 0.281
  4. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578.
    View in: PubMed
    Score: 0.277
  5. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res. 2022 10; 121:106928.
    View in: PubMed
    Score: 0.267
  6. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 09 10; 40(26):3032-3036.
    View in: PubMed
    Score: 0.266
  7. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Cancer. 2022 08 15; 128(16):3019-3026.
    View in: PubMed
    Score: 0.265
  8. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res. 2022 08; 119:106884.
    View in: PubMed
    Score: 0.264
  9. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035.
    View in: PubMed
    Score: 0.264
  10. Targeting CD123 in BPDCN: an emerging field. Expert Rev Hematol. 2021 11; 14(11):993-1004.
    View in: PubMed
    Score: 0.253
  11. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Biol Ther. 2020 02; 20(2):115-123.
    View in: PubMed
    Score: 0.223
  12. More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. N Engl J Med. 2019 02 14; 380(7):695-6.
    View in: PubMed
    Score: 0.210
  13. Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Curr Hematol Malig Rep. 2017 12; 12(6):592-597.
    View in: PubMed
    Score: 0.193
  14. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
    View in: PubMed
    Score: 0.075
  15. Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. Oncology (Williston Park). 2024 03 01; 38(3):104-106.
    View in: PubMed
    Score: 0.074
  16. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm. J Pediatr Hematol Oncol. 2023 11 01; 45(8):e1001-e1004.
    View in: PubMed
    Score: 0.072
  17. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228.
    View in: PubMed
    Score: 0.066
  18. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022 05; 36(5):1343-1350.
    View in: PubMed
    Score: 0.065
  19. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. 2022 01; 57(1):51-56.
    View in: PubMed
    Score: 0.063
  20. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma. 2021 12; 62(13):3296-3299.
    View in: PubMed
    Score: 0.062
  21. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021 04 01; 106(4):1047-1055.
    View in: PubMed
    Score: 0.061
  22. Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. J Dermatol. 2020 Oct; 47(10):e354-e355.
    View in: PubMed
    Score: 0.058
  23. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17; 124(3):385-92.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.